Clinical Trials Logo

Clinical Trial Summary

To get a better insight into the central conducting lymphatic system in adult volunteers with Noonan Syndrome (NS) without clinical symptoms or signs of lymphatic disease compared to NS and CardioFacioCutaan syndrome patients with severe lymphatic disease


Clinical Trial Description

Rationale: Noonan Syndrome Spectrum Disorders (NSSDs) are caused by pathogenic variants in genes of the Ras/MAPK signaling pathway, and belong to the RASopathy. Lymphatic disease occur in 36% of patients with Noonan Syndrome (NS) during their lifetime, with different symptoms, severity, and onset. However, it is unknown how many patients with RASopathy are exactly impaired with lymph flow disorders, since many of these patients have unrecognized symptoms and go undiagnosed. For example, patients diagnosed with primary lymphedema (which implies being without known etiologic cause) may have an anatomic or functional abnormality of the central conducting lymph system that is not diagnosed as the causative lymph flow problem. With the diagnosis being based on the symptoms and not on the underlying pathophysiological mechanism, therapy will focus on diminishing symptoms and not on healing the pathophysiological cause. To eventually improve therapeutic intervention, a better understanding of the pathophysiology is necessary, and may be found by studying the central conducting lymphatic system of patients with NS and lymphatic disease, and adult volunteers with Noonan Syndrome without lymphatic disease. Objective: To get a better insight into the central conducting lymphatic system in adult volunteers with Noonan Syndrome (NS) without clinical symptoms or signs of lymphatic disease compared to NS and CardioFacioCutaan syndrome patients with severe lymphatic disease and healthy volunteers. (ongoing study: (Lymphomics; improving the understanding the anatomy of the lymphatic system and the direction and velocity of lymph flow; approved by the Medical Ethics Committee at Radboud University Medical Center Nijmegen file number 2021-7514) Study design: A single center, prospective collection of data Study population: Adult volunteers with Noonan Syndrome without (a history of) complaints or signs of lymphatic disease. Intervention: Three questionnaires (general health, lymphatic abnormalities and general MRI safety) will be taken prior to the dynamic MR lymphangiography. In addition to standard physical examination and electronic patient file screening, for inclusion and exclusion purposes. Subsequently, the MR lymphangiography will be performed. After 24 hours, the subject will be called for a follow-up by phone. Main study parameters/endpoints: the anatomy of the central lymph vessels, the velocity and direction of lymph flow, which can be compared with reference values. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participation in this study places subjects at minimal risk. Subjects will undergo placement of a small needle in an inguinal lymph node on both sides, with very little risk of bleeding and/or infection, as with other minimal invasive procedures. The dynamic MR lymphangiography will take approximately two hours ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06267807
Study type Interventional
Source Radboud University Medical Center
Contact
Status Recruiting
Phase N/A
Start date March 27, 2024
Completion date June 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT02497131 - Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients Phase 2
Recruiting NCT01451502 - Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units N/A
Active, not recruiting NCT03264131 - BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma Phase 2
Completed NCT03744676 - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Phase 2
Completed NCT02335242 - Sildenafil for the Treatment of Lymphatic Malformations Phase 2
Completed NCT03135535 - Micro-mobile Foot Compression and Diabetic Foot Phase 2
Active, not recruiting NCT05441943 - Lymphaticovenous Anastomosis as Treatment for Lymphedema N/A
Withdrawn NCT05431179 - A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Phase 3
Recruiting NCT05731141 - A Prospective Natural History Study of Lymphatic Anomalies
Recruiting NCT03696784 - Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Phase 1
Completed NCT03709407 - "Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study" N/A
Active, not recruiting NCT02663297 - Administration of T Lymphocytes for Prevention of Relapse of Lymphomas Phase 1
Completed NCT05683444 - Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial Early Phase 1
Completed NCT02960841 - Effectiveness of Intracavitary Manual Lymphatic Drainage Phase 4
Recruiting NCT05263583 - Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma Phase 2
Terminated NCT02499627 - Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting Phase 2
Recruiting NCT03373019 - Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Phase 2
Recruiting NCT03602157 - Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Phase 1
Recruiting NCT02690545 - Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Phase 1/Phase 2
Completed NCT02744027 - Imaging of Lymphatic Anomalies N/A